Online Wellness Intervention for Primary Biliary Cholangitis (PBC)

Status Completed

Clinical Trial Summary

Primary biliary cholangitis (PBC) is a chronic autoimmune condition of the liver. Persons with PBC have high rates of liver disease-related symptoms and poor health-related quality of life - amongst the lowest of all chronic liver diseases. Patients and the Canadian PBC Society have identified the need for self-care tools to manage symptom burden. Building upon a previously developed online wellness program for inflammatory bowel disease (IBD), the researchers have developed a mind-body wellness module specific for patients with PBC. The 12 week module will be delivered online, and each week is made of an introduction video, 15-20 minutes of yoga, 10-15 minutes of meditation, behavior change tips, and nutrition tips. In a pre-post single arm feasibility study, the researchers will assess how acceptable this module is to patients through looking at rates of refusal, completion rates, and patient feedback. At the beginning and the end of the 12-week research study, participants will complete surveys to assess exploratory outcome measures including stress, anxiety, depression, resilience, quality of life, fatigue, and perceived ability to participate in the 12 week module. After the program, the research team will conduct interviews with participants to allow them to share their other feedback about the program. The researchers will also send surveys to the participants one month after the program ends to asses their continued satisfaction with and adherence to the program.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04791527
Study type	Interventional
Source	University of Alberta
Contact
Status	Completed
Phase	N/A
Start date	February 14, 2021
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04526665` - Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)	Phase 3
Recruiting	`NCT02931513` - sCD163 in PBC Patients - Assessment of Treatment Response
Active, not recruiting	`NCT02924701` - sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis
Completed	`NCT02659696` - Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis
Completed	`NCT02078882` - Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis	Phase 4
Completed	`NCT01603199` - High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis	N/A
Completed	`NCT01389973` - A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid	Phase 2
Completed	`NCT01857284` - Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis	Phase 3
Completed	`NCT05374200` - Mind-body Wellness Intervention in Primary Biliary Cholangitis (PBC)	N/A
Recruiting	`NCT02937012` - Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders	Phase 3
Completed	`NCT02376335` - B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis	Phase 2
Recruiting	`NCT01662973` - Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis	Phase 1/Phase 2
Active, not recruiting	`NCT04751188` - A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis	Phase 3
Recruiting	`NCT04514965` - Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
Recruiting	`NCT03668145` - Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis	N/A
Completed	`NCT02955602` - Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)	Phase 2
Completed	`NCT02557360` - Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis	Phase 4
Recruiting	`NCT01440309` - Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis	Phase 1
Completed	`NCT01249092` - Pentoxifylline for Primary Biliary Cirrhosis	Phase 2
Completed	`NCT01510860` - Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis	Phase 4